Literature DB >> 20667783

Circulating tumour cells in cancer patients: challenges and perspectives.

Klaus Pantel1, Catherine Alix-Panabières.   

Abstract

Ultrasensitive methods have been recently developed to detect circulating tumour cells (CTCs) in the peripheral blood and disseminated tumour cells (DTCs) in the bone marrow (BM) of cancer patients. Studies with these new methods indicate that BM is a common homing organ and a reservoir for DTCs derived from various organ sites including breast, prostate, lung and colon. Peripheral blood analyses, however, are more convenient for patients than invasive BM sampling and many research groups are currently assessing the clinical utility of CTCs for prognosis and monitoring response to systemic therapies. Moreover, molecular analyses of CTCs/DTCs have provided new insights into the biology of metastasis with important implications for the clinical management of cancer patients. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20667783     DOI: 10.1016/j.molmed.2010.07.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  214 in total

1.  Metastasis as a therapeutic target in prostate cancer: a conceptual framework.

Authors:  Konstantin Stoletov; David Bond; Katie Hebron; Srijan Raha; Andries Zijlstra; John D Lewis
Journal:  Am J Clin Exp Urol       Date:  2014-04

2.  Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Authors:  Steven M Santana; He Liu; Neil H Bander; Jason P Gleghorn; Brian J Kirby
Journal:  Biomed Microdevices       Date:  2012-04       Impact factor: 2.838

3.  Medical oncology: clinical value of circulating tumor cells in breast cancer.

Authors:  Stefan Sleijfer; John A Foekens
Journal:  Nat Rev Clin Oncol       Date:  2011-11-01       Impact factor: 66.675

Review 4.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

Review 5.  Blood-based tumor biomarkers in lung cancer for detection and treatment.

Authors:  Hirva Mamdani; Shahid Ahmed; Samantha Armstrong; Tony Mok; Shadia I Jalal
Journal:  Transl Lung Cancer Res       Date:  2017-12

Review 6.  NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Authors:  Yu Jen Jan; Jie-Fu Chen; Yazhen Zhu; Yi-Tsung Lu; Szu Hao Chen; Howard Chung; Matthew Smalley; Yen-Wen Huang; Jiantong Dong; Li-Ching Chen; Hsiao-Hua Yu; James S Tomlinson; Shuang Hou; Vatche G Agopian; Edwin M Posadas; Hsian-Rong Tseng
Journal:  Adv Drug Deliv Rev       Date:  2018-03-15       Impact factor: 15.470

7.  Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.

Authors:  Ja Hye Myung; Michael J Eblan; Joseph M Caster; Sin-Jung Park; Michael J Poellmann; Kyle Wang; Kevin A Tam; Seth M Miller; Colette Shen; Ronald C Chen; Tian Zhang; Joel E Tepper; Bhishamjit S Chera; Andrew Z Wang; Seungpyo Hong
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

8.  Capture and stimulated release of circulating tumor cells on polymer-grafted silicon nanostructures.

Authors:  Shuang Hou; Haichao Zhao; Libo Zhao; Qinglin Shen; Kevin S Wei; Daniel Y Suh; Aiko Nakao; Mitch A Garcia; Min Song; Tom Lee; Bin Xiong; Shyh-Chyang Luo; Hsian-Rong Tseng; Hsiao-hua Yu
Journal:  Adv Mater       Date:  2012-12-17       Impact factor: 30.849

9.  Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates.

Authors:  Qinglin Shen; Li Xu; Libo Zhao; Dongxia Wu; Yunshan Fan; Yiliang Zhou; Wei-Han Ouyang; Xiaochun Xu; Zhen Zhang; Min Song; Tom Lee; Mitch A Garcia; Bin Xiong; Shuang Hou; Hsian-Rong Tseng; Xiaohong Fang
Journal:  Adv Mater       Date:  2013-03-12       Impact factor: 30.849

Review 10.  Validation and clinical utility of prostate cancer biomarkers.

Authors:  Howard I Scher; Michael J Morris; Steven Larson; Glenn Heller
Journal:  Nat Rev Clin Oncol       Date:  2013-03-05       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.